touchRESPIRATORY caught up with Dr. Vijay Balasubramanian (UCSF Fresno, Fresno, CA, USA) to learn more around the challenges associated with treprostinil therapy in pulmonary arterial hypertension (PAH) and the impact treprostinil has had on the treatment paradigm since its approval.
The abstract ‘Rapid Titration of Parenteral Treprostinil to EXPEDITE Dosing of Oral Treprostinil‘ (Abstract number: P203) was presented at ATS 2022, 13-18 May 2022.
- What are the challenges of treprostinil therapy in patients with pulmonary arterial hypertension (PAH)? (0:40)
- Since its approval, what has been the impact of treprostinil on the treatment paradigm for PAH? (2:53)
Disclosures: Vijay Balasubramanian discloses receiving grant/ research support from United Therapeutics and has participated in speaker’s bureaus for Bayer, Janssen, and Boehringer Ingelheim.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ATS meeting 2022.
Share this Video
Related Videos In Pulmonary Hypertension
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Marc Simon, CHEST 2022: Clinical benefits with a higher dose of LIQ861 in pulmonary arterial hypertension – analysis of the LTI-301 clinical trial
INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (NCT03399604). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) around the aims, design and eligibility criteria of the LTI-301 clinical trial and the findings from […]
Marc Simon, CHEST 2022: LIQ861 for the treatment of pulmonary arterial hypertension
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil delivered through a device, which currently has tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) about LIQ861 and its potential advantages over conventional formulations of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!